कंपनी का अवलोकन
Sintx Technologies, Inc. is an advanced ceramics enterprise focused on the research, development, and commercialization of medical devices crafted from silicon nitride for biomedical, technical, and antipathogenic applications within the United States. The firm operates within the Healthcare sector, specifically targeting the Medical Devices industry, which positions it as a specialized manufacturer of high-performance materials for critical health infrastructure. Sintx currently maintains a market capitalization of $11.13M, generates annual revenue of $1.02M, and employs a workforce of 32 individuals to execute its strategic initiatives. These valuation and revenue figures indicate that the company functions as a micro-cap entity with limited operational scale, suggesting that its financial resilience relies heavily on successful product commercialization rather than diversified revenue streams or established market dominance.
वित्तीय स्वास्थ्य
The company reported trailing twelve-month revenue of $1.02M alongside a net income loss of $17,083,000 and an EBITDA of $-10,227,000. The substantial divergence between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and losses significantly outweigh gross profit generation, indicating a current phase of heavy investment or inefficiency. Free cash flow stands at $-2,919,625, which implies that the company is burning cash reserves to fund its operations and R&D efforts, thereby limiting immediate financial flexibility without external capital injections. The gross margin is recorded at 45.3%, suggesting that the silicon nitride devices command a premium price relative to their production costs, yet this is insufficient to cover broader operational expenditures. Conversely, the operating margin is severely negative at -787.6%, and the profit margin is listed at 0.0%, highlighting that the company is not generating operational profitability or net income on its sales volume. On the balance sheet, Sintx holds $4.14M in cash against $3.25M in debt, while the debt-to-equity ratio is reported at 110.92, indicating a highly leveraged position where debt obligations exceed equity capitalization. Despite the leverage, the current ratio of 1.51 suggests the company possesses adequate short-term assets to cover its current liabilities, providing a baseline for liquidity management. Return on Equity is -303.8% and Return on Assets is -69.8%, metrics that reveal management has yet to generate positive returns on the capital deployed, signaling that historical performance has been detrimental to shareholder value and asset efficiency.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -1.27, implying that the market anticipates a continued period of negative earnings or a long horizon before profitability is realized. The price-to-book ratio stands at 3.66, indicating that the market values the company at a significant premium over its book value, likely reflecting intangible assets or future potential despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 10.93 and the EV/EBITDA of -1.00 further underscore the speculative nature of the stock, as investors are pricing in future recovery rather than current earnings power. The 52-week high for the stock is $6.78 and the 52-week low is $1.71, placing the current trading range within a wide band of volatility that is common for micro-cap biotechnology or advanced materials firms. With a beta of 0.66, the stock exhibits lower volatility relative to the broader market, suggesting that price movements are less sensitive to general market swings compared to the typical equity index. These valuation dynamics suggest that the stock price is decoupled from traditional fundamental valuation models used for profitable corporations.
Growth & Income
Revenue growth year-over-year is -46.5%, while earnings growth is N/A due to the lack of positive earnings history, indicating that the company is contracting in terms of top-line revenue rather than expanding its market share. Since the earnings growth rate is not applicable due to persistent losses, the comparison between revenue and earnings implies that the decline in revenue is compounding the difficulty of achieving profitability, rather than earnings growing faster than revenue in a positive trajectory. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute income to shareholders and instead retains all capital for operational needs or research. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting a high-risk investment scenario typical of early-stage or struggling advanced ceramics manufacturers seeking a turnaround.